Zymeworks Stock Price, News & Analysis

Zymeworks (NASDAQ: ZYME) has initiated dosing in a global Phase 1 clinical trial for ZW191, targeting folate receptor-⍺ (FR⍺) expressing advanced solid tumors. The trial (NCT06555744) will evaluate safety and tolerability in treating advanced ovarian, endometrial, and non-small cell lung cancers. The two-part study aims to enroll 145 adult patients across North America, Europe, and Asia-Pacific. ZW191 showed promising pre-clinical results with greater anti-tumor activity compared to benchmark in FR⍺-expressing tumor models. FR⍺ is present in approximately 75% of high-grade serous ovarian carcinomas and 70% of lung adenocarcinomas.

Zymeworks (NASDAQ: ZYME) reported Q3 2024 financial results and corporate updates. Key highlights include: first patient dosed in Phase 1 trial of ZW171 for mesothelin-expressing cancers, presentation of preclinical data for ZW220 and ZW251 at EORTC-NCI-AACR conference, and completion of $30M share repurchase program. The company reported $374.9M in cash resources as of September 30, 2024, with projected runway into 2H 2027. Revenue was $45.3M for the nine months ended September 30, 2024, with a net loss of $99.2M.

Zymeworks (Nasdaq: ZYME) has announced its participation in six major healthcare investor conferences throughout November and December 2024. The clinical-stage biotechnology company will engage in various activities including one-on-one meetings, fireside chats, and panel discussions. The conferences include the UBS Global Healthcare Conference, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler Healthcare Conference, Citi's Global Healthcare Conference, and the Evercore HealthCONx Conference. At Citi's conference, management will participate in a panel discussion on 'Novel Antibody Mechanisms in Oncology'.

Zymeworks presented new preclinical data for two antibody-drug conjugate (ADC) candidates, ZW220 and ZW251, at the EORTC-NCI-AACR Conference. ZW220, targeting NaPi2b, shows potential for treating NSCLC, ovarian, and uterine cancers, with high tolerability in animal studies. ZW251, targeting glypican-3, demonstrates promise for hepatocellular carcinoma treatment. Both candidates incorporate Zymeworks' proprietary payload ZD06519. The company plans IND submissions for ZW220 in first half 2025 and ZW251 in second half 2025. The preclinical data suggests potential improvements over current standards of care, with favorable toxicology profiles and efficacy in various cancer models.

Zymeworks Inc. (Nasdaq: ZYME) has announced the dosing of the first patient in a Phase 1 clinical trial (NCT06523803) for ZW171, an investigational therapy targeting mesothelin (MSLN)-expressing cancers. The global study aims to evaluate the safety and tolerability of ZW171 in treating advanced ovarian cancer, non-small cell lung cancer (NSCLC), and other MSLN-expressing cancers.

The trial is designed as a two-part, open-label multi-center study, expected to enroll approximately 160 adult patients. Part 1 will focus on dose escalation in ovarian cancer and NSCLC patients, while Part 2 will involve dose expansion in three cohorts. The study will be conducted at sites in the United States, Europe, and the Asia-Pacific region.

Preclinical studies have shown ZW171's potential for potent, preferential killing of MSLN-overexpressing cells and stimulation of MSLN-dependent T cell activation, with potentially favorable tolerability.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced it will report its third quarter 2024 financial results after market close on October 31, 2024. Following this, the company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the financial results and provide a corporate update.

Zymeworks develops a diverse pipeline of novel, multifunctional biotherapeutics aimed at improving the standard of care for difficult-to-treat diseases. The event will be webcast live, and both dial-in details and webcast replays will be available on the company's investor relations website at https://ir.zymeworks.com/events-and-presentations.

Zymeworks Inc. (Nasdaq: ZYME) announced two presentations at the upcoming EORTC-NCI-AACR Conference in Barcelona, showcasing preclinical data for their antibody-drug conjugate (ADC) candidates ZW220 and ZW251. ZW220, targeting NaPi2b, demonstrated promising activity in non-small cell lung, ovarian, and uterine cancer models. ZW251, targeting glypican-3, showed compelling results in hepatocellular carcinoma models. Both candidates utilize Zymeworks' proprietary payload, ZD06519.

Chief Scientific Officer Paul Moore expressed excitement about the progress of these next-generation ADC programs, which are on track for IND filings in 2025. This follows the recent advancement of ZW171 and ZW191, currently in Phase 1 studies. The presentations highlight Zymeworks' ongoing development of novel biotherapeutics for difficult-to-treat cancers and other diseases.

Zymeworks Inc. (Nasdaq: ZYME) has reported an equity inducement award to Ms. Leone Patterson, their new Executive Vice President and Chief Business and Financial Officer. The award, granted under Nasdaq Stock Market Rule 5635(c), consists of a stock option to purchase 360,000 shares of the company's common stock. The option has an exercise price of $11.73 per share, equal to the closing price on August 30, 2024, and a maximum term of 10 years.

The option will vest over four years, with 25% vesting on the one-year anniversary of Ms. Patterson's start date (September 1, 2024), and the remaining 75% vesting monthly over the following three years. In the event of a change of control followed by termination without cause within 12 months, all unvested shares will fully vest.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced its participation in four upcoming investor conferences in September 2024. These events include:

• Wells Fargo Healthcare Conference on September 4 in Boston, MA
• Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 in New York, NY
• H.C. Wainwright 26th Annual Global Investment Conference on September 10 in New York, NY
• 2024 Cantor Global Healthcare Conference on September 18 in New York, NY

At each conference, Zymeworks' management will engage in one-on-one meetings and participate in fireside chats. The company, which focuses on developing novel, multifunctional biotherapeutics for difficult-to-treat diseases, aims to improve its visibility among investors and showcase its progress in the biotechnology sector.